Cholecystokinin octapeptide induces endogenous opioid-dependent anxiolytic effects in morphine-withdrawal rats

Neuroscience

Volumn 277, Issue , 2014, Pages 14-25

  Wen, D ^a   Sun, D ^a   Zang, G ^a   Hao, L ^a   Liu, X ^a   Yu, F ^a   Ma, C ^a   Cong, B ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Anxiety; CCK receptor; Cholecystokinin octapeptide; Elevated plus maze; Morphine withdrawal

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR; DEVAZEPIDE; MORPHINE; MU OPIATE RECEPTOR; NARCOTIC AGENT; OPIATE PEPTIDE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; NALOXONE;

ANIMAL; ANTAGONISTS AND INHIBITORS; ANXIETY; DOSE RESPONSE; MALE; METABOLISM; MORPHINE DEPENDENCE; PATHOPHYSIOLOGY; PSYCHOLOGY; RANDOMIZATION; SUBSTANCE WITHDRAWAL SYNDROME; WISTAR RAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; ELEVATED PLUS MAZE TEST; EXPERIMENTAL DESIGN; MOLECULAR INTERACTION; MORPHINE ADDICTION; NONHUMAN; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PROTEIN FUNCTION; RAT; TRANQUILIZING ACTIVITY; UPREGULATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BENZODIAZEPINONES; CENTRAL NERVOUS SYSTEM AGENTS; DEVAZEPIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MORPHINE; MORPHINE DEPENDENCE; NARCOTICS; OPIOID PEPTIDES; PHENYLUREA COMPOUNDS; RANDOM ALLOCATION; RATS, WISTAR; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, OPIOID, MU; SINCALIDE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84904473975     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.06.048     Document Type: Article

References (49)

1. Adams J.B., Pyke R.E., Costa J., Cutler N.R., Schweizer E., Wilcox C.S., Wisselink P.G., Greiner M., Pierce M.W., Pande A.C. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 1995, 15:428-434.
2. Baber N.S., Dourish C.T., Hill D.R. The role of CCK caerulein, and CCK antagonists in nociception. Pain 1989, 39:307-328.
3. Bilsky E.J., Bernstein R.N., Wang Z., Sadee W., Porreca F. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J Pharmacol Exp Ther 1996, 277:484-490.
4. Bourin M. Cholecystokinin as a target for neuropsychiatric drugs. Drug News Perspect 1998, 11:342-349.
5. Cesselin F. Opioid and anti-opioid peptides. Fundam Clin Pharmacol 1995, 9:409-433.
6. Christie M.J. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008, 154:384-396.
7. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides 1994, 15:731-755.
8. Dauge V., Derrien M., Durieux C., Noble F., Corringer P.J., Roques B.P. Study of induced effects by selective CCKB agonists cholecystokinin in the nociception and behavior in rodents. Therapie 1992, 47:531-539.
9. Derrien M., Noble F., Maldonado R., Roques B.P. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice. Neurosci Lett 1993, 160:193-196.
10. Dourish C.T., O'Neill M.F., Coughlan J., Kitchener S.J., Hawley D., Iversen S.D. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 1990, 176:35-44.
11. Gaveriaux-Ruff C., Matthes H.W., Peluso J., Kieffer B.L. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc Natl Acad Sci U S A 1998, 95:6326-6330.
12. Gellert V.F., Holtzman S.G. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J Pharmacol Exp Ther 1978, 205:536-546.
13. Goeldner C., Lutz P.E., Darcq E., Halter T., Clesse D., Ouagazzal A.M., Kieffer B.L. Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biol Psychiatry 2011, 69:236-244.
14. Heinricher M.M., Neubert M.J. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol 2004, 92:1982-1989.
15. Hernandez-Gomez A.M., Aguilar-Roblero R., Perez de la Mora M. Role of cholecystokinin-A and cholecystokinin-B receptors in anxiety. Amino Acids 2002, 23:283-290.
16. Hirosue Y., Inui A., Miura M., Nakajima M., Okita M., Himori N., Baba S., Kasuga M. Effects of CCK antagonists on CCK-induced suppression of locomotor activity in mice. Peptides 1992, 13:155-157.
17. Hodgson S.R., Hofford R.S., Norris C.J., Eitan S. Increased elevated plus maze open-arm time in mice during naloxone-precipitated morphine withdrawal. Behav Pharmacol 2008, 19:805-811.
18. Kaneyuki T., Morimasa T., Shohmori T. Action of peripherally administered cholecystokinin on monoaminergic and GABAergic neurons in the rat brain. Acta Med Okayama 1989, 43:153-159.
19. Koks S., Soosaar A., Voikar V., Volke V., Ustav M., Mannisto P.T., Bourin M., Vasar E. Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze. Neuropeptides 1998, 32:235-240.
20. Koks S., Soosaar A., Voikar V., Bourin M., Vasar E. BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze. Neuropeptides 1999, 33:63-69.
21. Kosaka T., Kosaka K., Tateishi K., Hamaoka Y., Yanaihara N., Wu J.Y., Hama K. GABAergic neurons containing CCK-8-like and/or VIP-like immunoreactivities in the rat hippocampus and dentate gyrus. J Comp Neurol 1985, 239:420-430.
22. Lu L., Huang M., Liu Z., Ma L. Cholecystokinin-B receptor antagonists attenuate morphine dependence and withdrawal in rats. Neuroreport 2000, 11:829-832.
23. Majewska M.D. Cocaine addiction as a neurological disorder: implications for treatment. NIDA Res Monogr 1996, 163:1-26.
24. Mannisto P.T., Lang A., Harro J., Peuranen E., Bradwejn J., Vasar E. Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn Schmiedebergs Arch Pharmacol 1994, 349:478-484.
25. Mitchell J.M., Bergren L.J., Chen K.S., Fields H.L. Cholecystokinin is necessary for the expression of morphine conditioned place preference. Pharmacol Biochem Behav 2006, 85:787-795.
26. Moran T.H., Schwartz G.J. Neurobiology of cholecystokinin. Crit Rev Neurobiol 1994, 9:1-28.
27. Moran T.H., Robinson P.H., Goldrich M.S., McHugh P.R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 1986, 362:175-179.
28. Nieto M.M., Guen S.L., Kieffer B.L., Roques B.P., Noble F. Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors. Neuroscience 2005, 135:305-313.
29. Noble F., Wank S.A., Crawley J.N., Bradwejn J., Seroogy K.B., Hamon M., Roques B.P. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999, 51:745-781.
30. Radke A.K., Gewirtz J.C. Increased dopamine receptor activity in the nucleus accumbens shell ameliorates anxiety during drug withdrawal. Neuropsychopharmacology 2012, 37:2405-2415.
31. Ragnauth A., Schuller A., Morgan M., Chan J., Ogawa S., Pintar J., Bodnar R.J., Pfaff D.W. Female preproenkephalin-knockout mice display altered emotional responses. Proc Natl Acad Sci U S A 2001, 98:1958-1963.
32. Rezayat M., Nikfar S., Zarrindast M.R. CCK receptor activation may prevent tolerance to morphine in mice. Eur J Pharmacol 1994, 254:21-26.
33. Rezayat M., Azizi N., Zarrindast M.R. On the mechanism(s) of cholecystokinin (CCK): receptor stimulation attenuates morphine dependence in mice. Pharmacol Toxicol 1997, 81:124-129.
34. Rezayof A., Nazari-Serenjeh F., Zarrindast M.R., Sepehri H., Delphi L. Morphine-induced place preference: involvement of cholinergic receptors of the ventral tegmental area. Eur J Pharmacol 2007, 562:92-102.
35. Sheehan M.J., de Belleroche J. Facilitation of GABA release by cholecystokinin and caerulein in rat cerebral cortex. Neuropeptides 1983, 3:429-434.
36. Sher L. The role of the endogenous opioid system in the pathogenesis of anxiety disorders. Med Hypotheses 1998, 50:473-474.
37. Spanagel R., Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999, 22:521-527.
38. Toru I., Maron E., Raag M., Vasar V., Nutt D.J., Shlik J. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers. Eur Neuropsychopharmacol 2013, 23:645-652.
39. Van Bockstaele E.J., Valentino R.J. Neuropeptide regulation of the locus coeruleus and opiate-induced plasticity of stress responses. Adv Pharmacol 2013, 68:405-420.
40. Wang X.J., Han J.S. Modification by cholecystokinin octapeptide of the binding of mu-, delta-, and kappa-opioid receptors. J Neurochem 1990, 55:1379-1382.
41. Wang X.J., Fan S.G., Ren M.F., Han J.S. Cholecystokinin-8 suppressed 3H-etorphine binding to rat brain opiate receptors. Life Sci 1989, 45:117-123.
42. Wang Z., Bilsky E.J., Porreca F., Sadee W. Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 1994, 54:PL339-350.
43. Wen D., Ma C.L., Cong B., Yu H.L., Yu F., Ni Z.Y., Li S.J. Interaction of CCK-8 and endogenous opioid system in the opioid dependence. Chin Pharmacol Bull 2010, 26:421-426.
44. Wen D., Cong B., Ma C., Yang S., Yu H., Ni Z., Li S. The effects of exogenous CCK-8 on the acquisition and expression of morphine-induced CPP. Neurosci Lett 2012, 510:24-28.
45. Wen D., Ma C.L., Zhang Y.J., Meng Y.X., Ni Z.Y., Li S.J., Cong B. Cholecystokinin receptor-1 mediates the inhibitory effects of exogenous cholecystokinin octapeptide on cellular morphine dependence. BMC Neurosci 2012, 13:63.
46. Wen D., Zang G., Sun D., Yang S., Yu F., Li S., Ma C., Cong B. Effects of CCK-8 on the reinstatement of morphine-induced CPP and expression of behavioral sensitization in rats. Neuroscience 2013, 238:230-241.
47. Woodruff G.N., Hill D.R., Boden P., Pinnock R., Singh L., Hughes J. Functional role of brain CCK receptors. Neuropeptides 1991, 19(Suppl):45-56.
48. Yu H., Wen D., Ma C., Meng Y., Li S., Ni Z., Cong B. Effects of exogenous cholecystokinin octapeptide on acquisition of naloxone precipitated withdrawal induced conditioned place aversion in rats. PLoS ONE 2012, 7:e41860.
49. Zhang Z., Schulteis G. Withdrawal from acute morphine dependence is accompanied by increased anxiety-like behavior in the elevated plus maze. Pharmacol Biochem Behav 2008, 89:392-403.